Rhenium-188-HEDP in the palliative treatment of bone metastases.

INTRODUCTION Rhenium-188-HEDP (188Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of bone pain due to metastases. As a product of a 188W/188Re generator it is convenient for clinical use. With a short physical half life of 16.9 hours and a maximal beta-energy of 2.1 MeV, it is suitable for therapy. METHODS We investigated the influence of 188Re-HEDP on pain relief, analgesic intake and impairment of bone marrow function in 15 patients. All patients were interviewed using standardized questions before, and 1, 2, 3, 4, 8, and 12 weeks after therapy. Blood samples were drawn weekly for 12 weeks, and a blood count was performed. Patients underwent gamma camera imaging to determine the radionuclide accumulation 4, 20, and 28 hours after therapy. The patients were treated with 1600 to 3459 MBq of 188Re-HEDP. RESULTS Patients showed an improvement of the Karnofsky performance index from 74 +/- 8% to 84 +/- 11% 12 weeks after therapy. This improvement was statistically significant (p = 0.001). Eighty percent of the patients described pain relief and reduction of analgesics. Twenty percent of the patients could discontinue their analgesics. Mean platelet count decreased from (284 +/- 84)*10(3)/microliter to (205 +/- 62)*10(3)/microliter, and mean leukocyte count from (7.5 +/- 1.5)*10(3)/microliter to (5.9 +/- 2.1)*10(3)/microliter after therapy. The maximal differences between the values of platelets and leukocytes before and after therapy were not statistically significant (p = 0.021 and p = 0.094). Prostate specific antigen decreased from 95 +/- 83 ng/ml to 41 +/- 21 ng/ml, the difference was not statistically significant (p = 0.443). The bone accumulation 4, 20, and 28 hours after therapy was 1.3 +/- 0.5%, 0.6 +/- 0.3%, and 0.45 +/- 0.2% of the injected dose of a single metastasis, and 57 +/- 17%, 15.5 +/- 2% and 11 +/- 3% in the whole body, respectively. The effective half-life of 188Re-HEDP was 15.3 +/- 3.0 hours in the bone metastases, and 11.4 +/- 2.8 hours in the whole body. This corresponds to a residence time of 0.22 +/- 0.25 hours in the bone metastases, and of 10.54 +/- 2.59 hours in the whole body. CONCLUSION In a small patient population, 188Re-HEDP therapy for bone pain palliation was effective and was associated with minimal toxicity.

[1]  M. Tian,et al.  Rhenium-188 HEDP To Treat Painful Bone Metastases , 2001, Clinical nuclear medicine.

[2]  H. Biersack,et al.  Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases , 2000, European Journal of Nuclear Medicine.

[3]  H. Maxon,et al.  Rhenium-188(Sn)HEDP for treatment of osseous metastases. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  E. Crawford,et al.  The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. , 1994, Urology.

[6]  P. V. van Rijk,et al.  Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D P Dearnaley,et al.  A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  J. Crook,et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.

[9]  J. A. Spicer,et al.  Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. , 1989, Radiographics : a review publication of the Radiological Society of North America, Inc.

[10]  E. Silberstein,et al.  Strontium-89 therapy for the pain of osseous metastases. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  J. Kropp,et al.  Rhenium-186-HEDP and Strontium-89-Chloride in Treatment of Metastatic Bone Pain , 1999 .

[12]  P. V. van Rijk,et al.  Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  W. Ellis,et al.  Advanced prostatic carcinoma. Early versus late endocrine therapy. , 1991, The Urologic clinics of North America.